EUCTR2008-005301-19-ES进行中（未招募）1 期
Estudio de fase 2, aleatorizado, a doble ciego y controlado con placebo para evaluar la seguridad y eficacia de FOLFIRI en combinación con AMG 479 o AMG 655 en comparación con FOLFIRI en el tratamiento de segunda línea del carcinoma colorrectal metastásico con KRAS mutado.A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safetyand Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Amgen Inc
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Disease Related
- •? Histologically confirmed adenocarcinoma of the colon or rectum in patients with
- •metastatic disease
- •? Mutant-type KRAS tumor status confirmed by central laboratory assessment of
- •formalin-fixed paraffin-embedded tumor tissue from the primary tumor or metastasis
- •? One and only one prior anti-cancer therapy regimen for metastatic disease
- •consisting of the combination of a fluoropyrimidine and oxaliplatin-based
- •chemotherapy with or without anti-VEGF therapy. Prior adjuvant or neoadjuvant
- •chemotherapy used prior to the onset of metastatic disease is permitted.
- •? Documented disease progression while receiving or ? 6 months after the last dose of prior first-line fluoropyrimidine and oxaliplatin-based chemotherapy with or without
- •bevacizumab for metastatic disease
- •? Measurable or non-measurable disease according to modified RECIST criteria.
- •Lesions must not be chosen from a previously irradiated field, unless there has been
- •documented disease progression in that field after irradiation and prior to
- •randomization. All sites of disease must be evaluated ? 28 days prior to randomization.
- •? Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Demographic
- •? Men or women 18 years of age or older at the time the informed consent is obtained
- •To be performed ? 7 days prior to randomization, unless otherwise specified:
- •? Hematologic function within the following limits:
- •? Absolute neutrophil count (ANC) ? 1.5 x 109/L
- •? Platelet count ? 100 x 109/L (without platelet transfusion ? 14 days prior to
- •randomization)
- •? Hemoglobin ? 9.0 g/dL
- •? Renal function within the following limits:
- •? Creatinine clearance (GFR) ? 40 mL/min calculated by the Cockcroft-Gault
- •method as follows:
- •o Male creatinine clearance = (140 ? age in years) x (weight in Kg) / (serum
- •creatinine in mg/dL x 72)
- •o Female creatinine clearance = (140 ? age) x (weight in Kg) x 0.85 / (serum
- •creatinine in mg/dL x 72)
- •? Hepatic function within the following limits
- •? Total bilirubin ? 1.5 mg/dL;
- •? Alkaline phosphatase ? 2.5 x ULN (if liver metastases, ? 5 x ULN)
- •? Aspartate aminotransferase (AST) ? 2.5 x ULN (if liver metastases, ? 5 x ULN)
- •? Alanine aminotransferase (ALT) ? 2.5 x ULN (if liver metastases, ? 5 x ULN)
- •? Coagulation function within the following limits:
- •? Partial thromboplastin time (PTT)/activated partial thromboplastin time (aPTT)
- •? 1.3 x ULN and international normalized ratio (INR) ? 1.5, unless subject is on
- •anti-coagulation therapy. Subjects on therapeutic anti-coagulation are eligible if:
- •o there is no bleeding and they are on a stable dose of anticoagulation therapy
- •(eg, warfarin with an INR of 2 to 3) for at least 14 days before randomization,
- •and o the patient has no active bleeding or pathological condition that carries high
- •risk of bleeding (eg, tumor involving major vessels or known varices)
- •? Subjects with diabetes (Type 1 or 2) must be adequately controlled with glycosylated hemoglobin (HgbA1c) ? 8% and fasting blood glucose level ?160 mg/dL; diabetic subjects who have recently had their glycemic control regimens adjusted and have documented fasting blood glucose concentrations ? 160 mg/dL may be considered, regardless of HgbA1c value, if per investigator discretion they are considered to have adequate glycemic function
- •? Negative pregnancy test ? 3 days prior to randomization (for woman of childbearing potential only)
- •? Competent to comprehend, sign, and date an institutional review board (IRB)/
- •Independent Ethics C
排除标准
- •Disease Related
- •? History or known presence of central nervous system (CNS) metastases
- •? History of other malignancy, except:
- •? Malignancy treated with curative intent and with no known active disease present
- •for ? 3 years prior to randomization and felt to be at low risk for recurrence by the
- •treating physician
- •? Adequately treated non-melanomatous skin cancer or lentigo maligna without
- •evidence of disease
- •? Adequately treated cervical carcinoma in situ without evidence of disease
- •? Prostatic intraepithelial neoplasia without evidence of prostate cancer
- •Cancer Therapy
- •? Prior irinotecan-based chemotherapy for advanced/metastatic disease
- •? Prior death receptor agonists (such as rhApo2/TRAIL [AMG 951]), apomab,
- •mapatumumab, lexatumumab, CS-1008), or other systemic IGF-1R antagonists
- •(such as CP-751, 951, MK0646, IMC-A12) in any setting.
- •? Systemic chemotherapy, hormonal therapy, immunotherapy or experimental or
- •approved anticancer proteins/antibodies therapy ? 21 days prior to randomization
- •? Radiotherapy ? 14 days prior to randomization. Subjects must have recovered from
- •all radiotherapy-related toxicities.
- •? Unresolved toxicities from prior anti-cancer therapy that, in the opinion of the
- •investigator, exclude subject from participation
- •Other Medications
- •? Course of systemic anti-infective that was completed ? 14 days before randomization
- •(exception can be made at the judgment of the investigator for oral treatment of an
- •uncomplicated urinary tract infection [UTI])
- •? Myocardial infarction, grade 2 or greater peripheral vascular disease,
- •cerebrovascular accident, transient ischemic attack, congestive heart failure,
- •percutaneous transluminal coronary angioplasty/stent, hypertension not stably
- •controlled pharmacologically, ongoing arrhythmias requiring medication or unstable
- •angina ? 24 weeks prior to randomization
- •? Pulmonary embolism, deep vein thrombosis, or other venous/arterial thromboembolic events ? 12 months before randomization
- •? Active inflammatory bowel disease or other bowel disease causing chronic diarrhea
- •(defined as ? CTCAE grade 2, [CTCAE version 3.0])
- •? Major surgical procedure ? 28 days before randomization or not yet recovered from
- •prior major surgery
- •? Anticipation of need for major elective surgical procedures during the course of the
- •? Minor surgical procedure ? 7 days before randomization or not yet recovered from
- •prior minor surgery (Uncomplicated placement of vascular access device, fine needle
- •aspiration, thoracocentesis or paracentesis ? 3 days prior to enrollment is
- •acceptable)
- •? Any co-morbid disease or condition that in the judgment of the investigator could
- •increase the risk of toxicity (such as clinically significant ascites)
- •? Subjects known to be human immunodeficiency virus positive or known to have
- •chronic or active hepatitis B or C infection
- •? Subject is currently enrolled in, or ? 30 days has passed since subject completed
- •another investigational device or drug study(s), or subject is receiving other
- •investigational agent(s)
- •? Woman of child-bearing potential is pregnant or is breast feeding
- •? Women of childbearing potential and men who do not consent to use adequate
- •contraception during the course of the study and 24 weeks (for men) or 12 weeks
- 另有 4 项未显示
研究者
相似试验
进行中（未招募）
1 期
Estudio de fase II, doble ciego, aleatorizado y controlado con placebo para determinar el efecto antiviral, la seguridad y la farmacocinética de la administración una vez al día durante 12 ó 24 semanas de BI 201335 NA, junto a la administración de interferón pegilado? 2a y ribavirina en pacientes con hepatitis C de genotipo 1 no tratados previamente.Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-? 2a and ribavirin (double-blinded, randomised, placebo-controlled, Phase II).infección crónica por el virus de la hepatitis C del genotipo 1chronic hepatitis C infection of genotype 1EUCTR2008-003538-11-ESBoehringer Ingelheim España, S.A.420
进行中（未招募）
1 期
Estudio en fase II aleatorizado, doble ciego y multicéntrico, para evaluar la eficacia de AZD2281 en el tratamiento de pacientes con cáncer de ovario seroso sensible al platino tras el tratamiento con dos o más regímenes que contienen platino.Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or more platinum containing regimensCáncer seroso de ovario sensible al platinoPlatinum sensitive serous ovarian cancerMedDRA version: 9.1Level: LLTClassification code 10033128Term: Ovarian cancerEUCTR2008-003439-18-ESAstraZeneca AB250
进行中（未招募）
不适用
Estudio de fase II, aleatorizado, doble ciego, controlado con placebo, del inhibidor de MEK GSK1120212 y Gemcitabina frente a placebo y Gemcitabina en sujetos con cáncer de páncreas metastásico. A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK inhibitor GSK1120212 plus Gemcitabine vs. Placebo plus Gemcitabine in Subjects with Metastatic Pancreatic CancerCáncer de páncreas metastásicoMedDRA version: 13Level: LLTClassification code 10033605Term: Cáncer pancreático metastásicoEUCTR2010-019578-34-ESGlaxoSmithKline, S.A.150
进行中（未招募）
不适用
Estudio fase II, a doble ciego, aleatorizado y multicéntrico, con esquema adaptativo de dosis, controlado con placebo y de grupos paralelos, para evaluar la eficacia, tolerabilidad y seguridad en base a parámetros de lesión observados mediante resonancia magnética, así como determinar la curva dosis - respuesta de BAF312 administrado oralmente en dosis única diaria en pacientes con Esclerosis Múltiple remitente recurrente.Esclerosis Múltiple remitente recurrenteMedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2008-008719-25-ESovartis Farmacéutica, S.A275
进行中（未招募）
1 期
Estudio Fase II, doble ciego, aleatorizado, controlado con placebo, de grupos paralelos, para explorar los posibles efectos beneficiosos de safinamida en la cognición, en pacientes no dementes con enfermedad de Parkinson (EP) idiopática y deterioro cognitivo.A double-blind, randomized, placebo-controlled, parallel-group Phase II study to explore the potential beneficial effects of safinamide on cognition in non-demented patients with idiopathic Parkinson's disease (PD) and cognitive impairment.Cognition in non-demented patients with idiopathic Parkinson's disease Cognición en sujetos no dementes con Enfermedad de Parkinson idiopáticaMedDRA version: 12.1Level: LLTClassification code 10061536Term: Parkinson's diseaseEUCTR2010-020109-34-ESMerck Serono S.A. - Geneva100